Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors

US11427567B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Qinda Ye · Claymont, US
• Jingwei Li · Beijing, CN
• Ken Mukai · Wilmington, US
• Brandon Smith · Chadds Ford, US
• Liangxing Wu · Wilmington, US
• Wenqing Yao · Kennett Square, US
• Min Ye · Ward, US
• Yingnan Chen · Wilmington, US
• Margaret Favata · North East, US
• Yvonne Lo · Hockessin, US

Key dates

• Filing date: Aug 13, 2020
• Grant date: Aug 30, 2022
• Expiry date: Aug 13, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q1/6886
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.